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Our approach to the way we look at genes or analyse DNA completely revolutionized after Kary Mullis envisioned a means of copying DNA in a chain reaction in 1983. Subsequently, he won the Nobel Prize for inventing this powerful PCR technology which has now become a ubiquitous tool in every life science laboratory, be it for basic or applied research, for diagnostics or for teaching undergraduate students.
There are many PCR machines in the market today, RNA is more difficult to work with because it has to be first reverse transcribed to cDNA. There are different approaches for reverse transcriptase PCR.
A major advance has been the development of real time PCR systems where the amount of amplicon generated is monitored and quantitated as the reaction progresses using fluorescent signals which increase in proportion to the amount of PCR product accumulated in the reaction. Different reporter molecules like TaqMan fluorogenic probes, molecular beacons or the intercalating dye SYBR Green have been used for generation of fluorescence.
In the last few years, 2 major milestones have been the development of microarrays and RNA interference (RNAi). Real time RT-PCR has also been used for validation of microarray results and for confirming the levels of gene knockdown in siRNA experiments.
In this issue of the journal, there are two articles on the application of PCR for diagnosis of retinoblastoma and Fragile X syndrome. A cost effective and quick strategy of multiplex PCR has been described for amplification of 12 CGA codons which account for about half of the retinoblastoma suspectibility gene mutations. In the case of Fragile X syndrome, the authors have used PCR for initial screening of triplet repeat expansions for FRAXA and FRAXE mutations with a view to cut down the number of cases requiring Southern blot hybridization.
